UK-based human genome research platform Repositive raises £2.5 million Series A

UK-based Repositive, which has created a portal for accessing human genomic research data, has closed a £2.5 million Series A round. The investment was led by Ananda Social Venture Fund and Force Over Mass Capital. Amadeus Capital Partners and Jonathan Milner have also increased their investments, after previously participated in a seed round.

Through Repositive's platform, researchers and scientists are able toeasily access data from a range of global sources, and make their data accessible to collaborators. The platform allows researchers to interact, identify relevant data, and benefit from community feedback and data annotations.

Since its launch in September 2016, the platform has grown to over one million data sets, and the company has expanded their global user base across pharma, biotech and academia.

“Repositive is unique in identifying, providing access and democratising genomic data without ethical compromise," commented Lennart Hergel, Investment Director for Ananda Social Venture Fund in a statement. "We believe that this will reduce time and cost for diagnostics and drug development, therefore enabling better and affordable access to new and personalized therapies for patients. We have confidence that the energetic and capable Repositive team will drive this impact and create a very successful company on a commercial level.”

Repositive plans to use the new investment to expand the premium features available to its users and develop more commercial products and services for the genomics R&D industry.

Read more: Amadeus Capital Partners (Press release)